Fortrea Appoints Machelle Sanders to Board of Directors
16 Maggio 2024 - 10:05PM
Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract
research organization (“CRO”), today announced the appointment of
Machelle Sanders to the Company’s Board of Directors. Ms. Sanders
has served as North Carolina’s Secretary of Commerce since February
2021 and brings strong domain expertise from more than 30 years of
operational and quality assurance roles in pharmaceutical and
biotechnology companies.
“Machelle’s impressive background in life sciences and public
service enables her to bring a unique and welcome perspective to
our Board,” said Tom Pike, chairman and CEO. “She is a highly
respected leader, who understands our customers and what it takes
to deliver high-quality services around the globe. Machelle’s
experience and leadership acumen will be an asset to Fortrea as we
create value for all our stakeholders by advancing our
differentiation strategy and organization, inspired by our purpose
of delivering life-changing treatments to patients faster.”
“I’m delighted to join Fortrea’s Board as the Company forges a
new path in the CRO sector,” said Ms. Sanders. “I recognize the
pivotal role that CROs play in bringing new treatments to market
and the difference they can make for pharmaceutical and
biotechnology innovators around the world. I look forward to
sharing my insights and partnering with Tom and the Fortrea team on
its journey ahead.”
About Machelle Sanders
Machelle Sanders was appointed Secretary of Commerce for North
Carolina by Governor Cooper in February 2021. She served as
Secretary of the North Carolina Department of Administration from
January 2017 to February 2021. Ms. Sanders brings strong management
and leadership experience as a seasoned pharmaceutical and
biotechnology executive, previously serving as vice president of
manufacturing and general manager of Biogen’s largest manufacturing
facility in Research Triangle Park, North Carolina. She has held
leadership positions overseeing manufacturing, global quality
assurance and quality control functions at Biogen, Purdue
Pharmaceuticals, and AkzoNobel. Ms. Sanders has served on the board
of three biotechnology companies and currently is a board member of
BioCryst Pharmaceuticals. She received a B.S. in biochemistry from
North Carolina State University and a master’s degree in health
administration from Pfeiffer University.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical
development and patient access solutions to the life sciences
industry. We partner with emerging and large biopharmaceutical,
biotechnology, medical device and diagnostic companies to drive
healthcare innovation that accelerates life-changing therapies to
patients. Fortrea provides phase I-IV clinical trial management,
clinical pharmacology, consulting services, differentiated
technology enabled trial solutions and post-approval services.
Fortrea’s solutions leverage three decades of experience
spanning more than 20 therapeutic areas, a passion for scientific
rigor, exceptional insights and a strong investigator site network.
Our talented and diverse team working in more than 90 countries is
scaled to deliver focused and agile solutions to customers
globally.
Learn more about how Fortrea is becoming a transformative force
from pipeline to patient at Fortrea.com and follow us
on LinkedIn and X (formerly Twitter)
@Fortrea.
Fortrea Contacts:Hima Inguva (Investors) –
877-495-0816, hima.inguva@fortrea.comSue Zaranek (Media) –
919-943-5422, media@fortrea.comKate Dillon (Media) – 646-818-9115,
kdillon@prosek.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c79136bb-05be-4e64-95d6-e195c95259f4
Grafico Azioni Fortrea (NASDAQ:FTRE)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Fortrea (NASDAQ:FTRE)
Storico
Da Dic 2023 a Dic 2024